Reaction

Gastric Perforation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,688 reports · 74 co-occurring drugs

As of the last recalculation, Gastric Perforation appears in 2,688 FAERS reports alongside 74 co-occurring drug terms. The strongest observed disproportionality signal is LENVATINIB (PRR 12.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Lenvatinib	51	12.3	12.3
Cisplatin	106	10.9	10.9
Bevacizumab	164	10.9	10.9
Irinotecan Hydrochloride	17	10.3	10.3
Oxaliplatin	92	9.9	9.9
Leucovorin Calcium	22	9.0	9.0
Fluorouracil Cream, 0.5%	84	8.8	8.8
Capecitabine	99	8.7	8.7
Fluorouracil	84	8.6	8.7
Acetaminophen, Aspirin, And Caffeine	21	7.8	7.8
Doxepin	10	7.7	7.7
Valganciclovir Hydrochloride Powder,	12	7.6	7.7
Febuxostat Tablets 40 Mg	10	7.6	7.6
Febuxostat Tablets 80 Mg	10	7.6	7.6
Acetaminophen, Aspirin (Nsaid) And Caffeine	16	7.3	7.3
Sucralfate Oral	13	7.1	7.1
Sucralfate Oral Suspension	13	7.1	7.1
Doxepin Hydrochloride	11	6.8	6.8
Diclofenac	73	6.7	6.7
Granisetron Hydrochloride	9	6.7	6.7
Atezolizumab	32	6.4	6.5
Valganciclovir	15	6.2	6.2
Valganciclovir Hydrochloride	15	6.2	6.2
Paclitaxel	77	6.2	6.2
Diclofenac Sodium 1%	28	6.1	6.1
Diclofenac Sodium Topical	28	6.1	6.1
Diclofenac Sodium Topical Gel, 1%	28	6.1	6.1
Terazosin Hydrochloride	7	6.1	6.1
Paclitaxel (Aibumin-Bound)	63	6.1	6.1
Granisetron	8	5.9	5.9
Aprepitant	14	5.9	5.9
Docetaxel Anhydrous	50	5.8	5.8
Docetaxel	50	5.8	5.8
Remdesivir	10	5.8	5.8
Doxorubicin	63	5.6	5.6
Voriconazole Injection	15	5.4	5.4
Prednisolone Acetate	7	5.2	5.3
Doxyclycline Hyclate	11	5.0	5.0
Diclofenac Sodium	93	4.9	4.9
Mycophenilic Acid	13	4.9	4.9
Upadacitinib	50	4.8	4.8
Polatuzumab Vedotin	6	4.8	4.8
Regorafenib	7	4.7	4.7
Febuxostat	10	4.6	4.6
Voriconazole	18	4.6	4.6
Gemcitabine Hydrochloride	31	4.6	4.6
Nintedanib	18	4.5	4.5
Pembrolizumab	59	4.4	4.4
Gemcitabine	22	4.4	4.4
Naproxen Sodium Tablet	29	4.3	4.3
Thiotepa	5	4.1	4.1
Imatinib	9	4.0	4.0
Doxorubicin Hydrochloride	16	3.8	3.8
Sunitinib Malate	19	3.8	3.8
Amphetamine	4	3.7	3.7
Sorafenib	10	3.7	3.7
Rivastigmine	9	3.7	3.7
Pazopanib Hydrochloride	12	3.4	3.4
Trastuzumab	28	3.2	3.2
Pegaspargase	5	3.2	3.2
Nivolumab	39	3.2	3.2
Fam-Trastuzumab Deruxtecan-Nxki	4	3.1	3.1
Carboplatin	49	3.0	3.0
Carfilzomib	11	3.0	3.0
Trifluridine And Tipiracil	4	2.9	2.9
Cetuximab	11	2.7	2.7
Vemurafenib	4	2.6	2.6
Crizotinib	4	2.4	2.4
Obinutuzumab	5	2.4	2.4
Cabozantinib	14	2.3	2.3
Axitinib	5	2.0	2.0
Durvalumab	5	1.9	1.9
Velpatasvir And Sofosbuvir	3	1.8	1.8
Dimethyl Fumarate	27	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.